261 related articles for article (PubMed ID: 26401584)
1. Correlates of Protection Following Vaccination with Inactivated Porcine Circovirus 2 Vaccines.
Zanotti C; Martinelli N; Lelli D; Amadori M
Viral Immunol; 2015 Dec; 28(10):600-8. PubMed ID: 26401584
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity in swine induced by Porcine Circovirus 2b inactivated vaccines with different antigen payload.
Guarneri F; Tresoldi ET; Sarli G; Boniotti MB; Lelli D; Barbieri I; Bacci B; D'Annunzio G; Amadori M
Vet Microbiol; 2021 Jan; 252():108887. PubMed ID: 33276254
[TBL] [Abstract][Full Text] [Related]
3. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
[TBL] [Abstract][Full Text] [Related]
4. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cell-mediated immune responses against porcine circovirus type 2 (PCV2) Cap and Rep proteins after vaccination with a commercial PCV2 sub-unit vaccine.
Fort M; Sibila M; Nofrarías M; Pérez-Martín E; Olvera A; Mateu E; Segalés J
Vet Immunol Immunopathol; 2012 Nov; 150(1-2):128-32. PubMed ID: 23010221
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge.
Park KH; Oh T; Yang S; Cho H; Kang I; Chae C
Vet Microbiol; 2019 Apr; 231():87-92. PubMed ID: 30955830
[TBL] [Abstract][Full Text] [Related]
7. Comparison of sow and/or piglet vaccination of 3 commercial porcine circovirus type 2 (PCV2) single-dose vaccines on pigs under experimental PCV2 challenge.
Oh Y; Seo HW; Park C; Chae C
Vet Microbiol; 2014 Aug; 172(3-4):371-80. PubMed ID: 24970364
[TBL] [Abstract][Full Text] [Related]
8. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China.
Li J; Yu T; Wang X; Zhou J; Gao R; Zhang F; Gao X; Gao S; Liu X
Virol J; 2015 Jul; 12():113. PubMed ID: 26220290
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b.
Jeong J; Park C; Choi K; Chae C
Vet Microbiol; 2015 May; 177(1-2):43-52. PubMed ID: 25790733
[TBL] [Abstract][Full Text] [Related]
11. Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge.
Opriessnig T; Karuppannan AK; Halbur PG; Calvert JG; Nitzel GP; Matzinger SR; Meng XJ
Vaccine; 2020 Feb; 38(8):1975-1981. PubMed ID: 31974016
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Fostera™ PCV MH) under experimental conditions.
Park C; Jeong J; Choi K; Chae C
Vaccine; 2016 Jan; 34(2):270-275. PubMed ID: 26626212
[TBL] [Abstract][Full Text] [Related]
13. A pilot comparative study of recombinant protein and whole-virus inactivated vaccines against porcine circovirus type 2 in conventionally reared pigs.
Choi JY; Lyoo KS; Kim K; Do VT; Lee KW; Hahn TW
Res Vet Sci; 2019 Apr; 123():192-194. PubMed ID: 30682582
[TBL] [Abstract][Full Text] [Related]
14. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain.
Opriessnig T; Gerber PF; Xiao CT; Mogler M; Halbur PG
Vaccine; 2014 Jan; 32(2):230-7. PubMed ID: 24269319
[TBL] [Abstract][Full Text] [Related]
15. Clinical, virological, immunological and pathological evaluation of four porcine circovirus type 2 vaccines.
Seo HW; Han K; Park C; Chae C
Vet J; 2014 Apr; 200(1):65-70. PubMed ID: 24618398
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four commercial one-dose porcine circovirus type 2 (PCV2) vaccines administered to pigs challenged with PCV2 and porcine reproductive and respiratory syndrome virus at 17 weeks postvaccination to control porcine respiratory disease complex under Korean field conditions.
Park C; Seo HW; Han K; Chae C
Clin Vaccine Immunol; 2014 Mar; 21(3):399-406. PubMed ID: 24403524
[TBL] [Abstract][Full Text] [Related]
17. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2.
Opriessnig T; Gerber PF; Xiao CT; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2014 Jul; 32(34):4342-8. PubMed ID: 24929119
[TBL] [Abstract][Full Text] [Related]
18. Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge.
Seo HW; Oh Y; Han K; Park C; Chae C
BMC Vet Res; 2012 Oct; 8():194. PubMed ID: 23078878
[TBL] [Abstract][Full Text] [Related]
19. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
[TBL] [Abstract][Full Text] [Related]
20. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
